BFC Planning’s Cadrenal Therapeutics CVKD Stock Holding History
Bought
Maintained
Sold
Other funds holding CVKD
BFC Planning's CVKD Position: Q3 2026 in Review
BFC Planning held its Cadrenal Therapeutics (CVKD) position steady in Q3 2026 at 100 shares worth $108. The position accounts for ﹤0.01% of the portfolio, ranked #3385.
BFC Planning first reported a position in CVKD in Q2 2026 and has held it in 2 quarters since. The position peaked at $334 in Q2 2026. 23 funds tracked by Wall St. Rank hold CVKD as of Q3 2026.
- BFC Planning held 100 shares of Cadrenal Therapeutics worth $108 as of Q3 2026.
- BFC Planning left its Cadrenal Therapeutics share count unchanged in Q3 2026.
- Cadrenal Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3385 holding.
- BFC Planning first reported a position in Cadrenal Therapeutics in Q2 2026 and has held it in 2 quarters since.
- BFC Planning's Cadrenal Therapeutics position peaked at $334 in Q2 2026.
- 23 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.